Pseudogenes such as CTNNAP1, NMRAL2P, and DUXAP8 show therapeutic potential, advocating for further research into their mechanisms to enhance CRC diagnostics and personalized care. This evidence concerns the gene NMRAL2P and colorectal carcinoma.